Please assess the completion status of the following clinical trial:

Trial Title: Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically confirmed diagnosis of Andersen-Tawil Syndrome, as defined by at least two of the following three features:~  1. Neuromuscular Feature~     * Presence of clear-cut episodes of transient muscle weakness with or without a fixed deficit that is typical with rest after exertion or prolonged rest, OR~    * An atypical history with specific exam findings (absent reflexes with normal sensation ictally), OR~    * Unexplained intraictal hypokalemia, OR~    * An abnormal nerve conduction exercise test~ 2. Cardiac Feature~     * Prolonged QTc interval on 12-lead electrocardiogram (ECG), according to standard criteria, AND/OR~    * Ventricular ectopy, including uniform or multifocal PVCs, polymorphic VT, or bidirectional VT~ 3. Physical Feature (at least two of the below five features)~     * Low set ears~    * Hypertelorism~    * Small mandible~    * Clinodactyly~    * Syndactyly~    * Micromelia of hands or feet~-OR-~* One of the three above criteria, with at leat one other family member meeting two criteria~-OR-~* Not meeting clinical criteria but possessing the KCNJ2 mutation~* An average frequency of at least one neuromuscular symptom (attack of weakness) per week~Exclusion Criteria:~* Sulfa allergy~* Renal impairment, as defined by serum creatine greater than 1.5 mg/dl~* History of renal calculi~* Cardiac disease or other disease that would make potassium supplementation or acetazolamide treatment inadvisable~* Diabetes mellitus~* Currently taking quinidine~* Pregnant

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive either potassium or placebo during six 3-week-long treatments, as randomly determined. Participants will then continue to receive potassium, if tolerated, and also either acetazolamide or placebo during another six 3-week-long treatments, as randomly determined.

Based on this trial design, predict the completion outcome and termination type (if applicable).